Her2 treatment drugs

If the IHC result is 1, the cancer is considered HER2-negative. These cancers do not usually respond to treatment with drugs that target HER2, but new research shows that certain HER2 drugs might help in some cases (see below). If the IHC result is 2, the HER2 status of the tumor is not clear and is called equivocal. This means that the

HER2-positive breast cancers have a lot of a protein called HER2 on the surface of their cells. The HER2 protein is an important driver of cell growth and survival. HER2-targeted therapies are used to treat HER2-positive breast cancers. They have no role in the treatment of HER2-negative cancers. Testing for HER2 status

Emerging new drugs (e.g, antibody–drug conjugates) targeting HER2 have dramatically improved treatment outcomes for HER2-positive metastatic breast cancer.

HR and HER2 status determine drug treatment options. Current treatments. HER2-positive breast cancer. Approximately 20% of breast cancers are HER2-positive. Trastuzumab (Herceptin, Roche) was the

HER2-targeted therapies are designed to treat HER2-positive breast cancers. They have no role in the treatment of HER2-negative cancers.

Background: Treatment of HER2-positive (HER2) breast cancer is based on the use of drugs targeting HER2 (anti-HER2 treatment). Trastuzumab is the current

Trastuzumab and other drugs called monoclonal antibodies that target HER2 have been quite successful as treatments for HER2-positive breast

Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-positive cancers.

There are many ongoing studies of potential HER2-mutant lung cancer treatments that are very exciting, Dr. Li said. Some are looking at other antibody drug conjugates that bind to HER2 or new small-molecule drugs that block the activity of HER2.